Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1995-10-30
2001-11-13
Kunz, Gary L. (Department: 1647)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S320100, C435S325000, C435S252300, C435S254400, C530S350000, C536S023500
Reexamination Certificate
active
06316217
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use.
BACKGROUND OF THE INVENTION
The transforming growth factor-&bgr; (TGF-&bgr;) superfamily consists of a family of structurally-related proteins, including three different mammalian isoforms of TGF-&bgr; (TGF-&bgr;1, &bgr;2 and &bgr;3), activins, inhibins, müllerian-inhibiting substance and bone morphogenic proteins (BMPS) (for reviews see Roberts and Sporn, (1990) Peptide Growth Factors and Their Receptors, Pt.1, Sporn and Roberts, eds. (Berlin: Springer-Verlag) pp 419-472; Moses et al (1990) Cell 63, 245-247). The proteins of the TGF-&bgr; superfamily have a wide variety of biological activities. TGF-&bgr; acts as a growth inhibitor for many cell types and appears to play a central role in the regulation of embryonic development, tissue regeneration, immuno-regulation, as well as in fibrosis and carcinogenesis (Roberts and Sporn (199) see above).
Activins and inhibins were originally identified as factors which regulate secretion of follicle-stimulating hormone secretion (Vale et al (1990) Peptide Growth Factors and Their Receptors, Pt.2, Sporn and Roberts, eds. (Berlin: Springer-Verlag) pp.211-248). Activins were also shown to induce the differentiation of haematopoietic progenitor cells (Murata et al (1988) Proc. Natl. Acad. Sci. USA II, 2434-2438; Eto et al (1987) Biochem. Biophys. Res. Commun. 142, 1095-1103) and induce mesoderm formation in Xenopus embryos (Smith et al (1990) Nature 3, 729-731; van den Eijnden-Van Raaij et al (1990) Nature 345, 732-734).
BMPs or osteogenic proteins which induce the formation of bone and cartilage when implanted subcutaneously (Wozney et al (1988) Science 242, 1528-1534), facilitate neuronal differentiation (Paralkar et al (1992) J. Cell Biol. 119, 1721-1728) and induce monocyte chemotaxis (Cunningham et al (1992) Proc. Natl. Acad. Sci. USA 89, 11740-11744). Müllerian-inhibiting substance induces regression of the Müllerian duct in the male reproductive system (Cate et al (1986) Cell 45, 685-698), and a glial cell line-derived neurotrophic factor enhances survival of midbrain dopaminergic neurons (Lin et al (1993) Science 260, 1130-1132). The action of these growth factors is mediated through binding to specific cell surface receptors.
Within this family, TGF-&bgr; receptors have been most thoroughly characterized. By covalently cross-linking radio-labelled TGF-&bgr; to cell surface molecules followed by polyacrylamide gel electrophoresis of the affinity-labelled complexes, three distinct size classes of cell surface proteins (in most cases) have been identified, denoted receptor type I (53 kd), type II (75 kd), type III or betaglycan (a 300 kd proteoglycan with a 120 kd core protein) (for a review see Massague (1992) Cell 69 1067-1070) and more recently endoglin (a homodimer of two 95 kd subunits) (Cheifetz a& al (1992) J. Biol. Chem. 267 19027-19030). Current evidence suggests that type I and type II receptors are directly involved in receptor signal transduction (Segarini et al (1989) Mol. Endo., 3, 261-272; Laiho et al (1991) J. Biol. Chem. 266, 9100-9112) and may form a heteromeric complex; the type II receptor is needed for the binding of TGF-&bgr; to the type I receptor and the type I receptor is needed for the signal transduction induced by the type II receptor (Wrana et al (1992) Cell, 71, 1003-1004). The type III receptor and endoglin may have more indirect roles, possibly by facilitating the binding of ligand to type II receptors (Wang et al (1991) Cell, 67 797-805; López-Casillas et al (1993) Cell, 73 1435-1444).
Binding analyses with activin A and BMP4 have led to the identification of two co-existing cross-linked affinity complexes of 50-60 kDa and 70-80 kDa on responsive cells (Hino et al (1989) J. Biol. Chem. 264, 10309-10314; Mathews and Vale (1991), Cell 68, 775-785; Paralker et al (1991) Proc. Natl. Acad. Sci. USA 87, 8913-8917). By analogy with TGF-&bgr; receptors they are thought to be signalling receptors and have been named type I and type II receptors.
Among the type II receptors for the TGF-&bgr; superfamily of proteins, the cDNA for the activin type II receptor (Act RII) was the first to be cloned (Mathews and Vale (1991) Cell 65, 973-982). The predicted structure of the receptor was shown to be a transmembrane protein with an intracellular serine/threonine kinase domain. The activin receptor is related to the
C. elegans
daf-1 gene product, but the ligand is currently unknown (Georgi et al (1990) Cell 61, 635-645). Thereafter, another form of the activin type II receptor (activin type IIB receptor), of which there are different splicing variants (Mathews et al (1992), Science 225, 1702-1705; Attisano et al (1992) Cell 68, 97-108), and the TGF-&bgr; type II receptor (T&bgr;RII) (Lin et al (1992) Cell 68, 775-785) were cloned, both of which have putative serine/threonine kinase domains.
SUMMARY OF THE INVENTION
The present invention involves the discovery of related novel peptides, including peptides having the activity of those defined herein as SEQ ID Nos. 2, 4, 8, 10, 12, 14, 16 and 18. Their discovery is based on the realisation that receptor serine/threonine kinases form a new receptor family, which may include the type II receptors for other proteins in the TGF-&bgr; superfamily. To ascertain whether there were other members of this family of receptors, a protocol was designed to clone ActRII/daf I related cDNAs. This approach made use of the polymerase chain reaction (PCR), using degenerate primers based upon the amino-acid sequence similarity between kinase domains of the mouse activin type II receptor and daf-I gene products.
This strategy resulted in the isolation of a new family of receptor kinases called Activin receptor like kinases (ALK's) 1-6. These cDNAs showed an overall 33-39% sequence similarity with ActRII and TGF-&bgr; type II receptor and 40-92% sequence similarity towards each other in the kinase domains.
Soluble receptors according to the invention comprise at least predominantly the extracellular domain. These can be selected from the information provided herein, prepared in conventional manner, and used in any manner associated with the invention.
Antibodies to the peptides described herein may be raised in conventional manner. By selecting unique sequences of the peptides, antibodies having desired specificity can be obtained.
The antibodies may be monoclonal, prepared in known manner. In particular, monoclonal antibodies to the extracellular domain are of potential value in therapy.
Products of the invention are useful in diagnostic methods, e.g. to determine the presence in a sample for an analyte binding therewith, such as in an antagonist assay. Conventional techniques, e.g. an enzyme-linked immunosorbent assay, may be used.
Products of the invention having a specific receptor activity can be used in therapy, e.g. to modulate conditions associated with activin or TGF-&bgr; activity. Such conditions include fibrosis, e.g. liver cirrhosis and pulmonary fibrosis, cancer, rheumatoid arthritis and glomeronephritis.
REFERENCES:
patent: 5521295 (1996-05-01), Pacifici et al.
patent: 5538892 (1996-07-01), Donahoe et al.
patent: 5614609 (1997-03-01), Iba{overscore (n)}ez et al.
patent: WO9507982 (1995-03-01), None
Matthews et al.,Science, pp. 1702-1705 (1992).
Attisano et al.,Cell, 68:97-108 (1992).
Lin et al.,Cell, 68:775-785 (1992).
Matthews et al.,Cell, 65:973-982 (1991).
Ebner et al., “Cloning of a Type 1 TGF-&bgr; Receptor And Its Effect on TGF-&bgr; Binding To The Type II Receptor”, Science 260: 1344-1348 (May 28, 1993).
Dijke Peter ten
Franzen Petra
Heldin Carl-Henrik
Miyazono Kohei
Yamashita Hidetoshi
Fulbright & Jaworski LLP
Kunz Gary L.
Landsman Robert S.
Ludwig Institute for Cancer Research
LandOfFree
Activin receptor-like kinases, proteins having serine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Activin receptor-like kinases, proteins having serine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activin receptor-like kinases, proteins having serine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2588303